---
layout: default
title: LMOD+: A Comprehensive Multimodal Dataset and Benchmark for Developing and Evaluating Multimodal Large Language Models in Ophthalmology
---

# LMOD+: A Comprehensive Multimodal Dataset and Benchmark for Developing and Evaluating Multimodal Large Language Models in Ophthalmology

<div class="paper-toolbar">
  <a href="https://arxiv.org/abs/2509.25620" class="toolbar-btn" target="_blank">üìÑ arXiv: 2509.25620v1</a>
  <a href="https://arxiv.org/pdf/2509.25620.pdf" class="toolbar-btn" target="_blank">üì• PDF</a>
  <button class="toolbar-btn favorite-btn" data-arxiv-id="2509.25620v1" data-paper-url="__CURRENT_PAGE__" onclick="toggleFavorite(this, '2509.25620v1', 'LMOD+: A Comprehensive Multimodal Dataset and Benchmark for Developing and Evaluating Multimodal Large Language Models in Ophthalmology')" title="Ê∑ªÂä†Âà∞Êî∂ËóèÂ§π">‚òÜ Êî∂Ëóè</button>
  <button class="toolbar-btn" onclick="copyLinkToClipboard(this)">üîó ÂàÜ‰∫´</button>
</div>


**‰ΩúËÄÖ**: Zhenyue Qin, Yang Liu, Yu Yin, Jinyu Ding, Haoran Zhang, Anran Li, Dylan Campbell, Xuansheng Wu, Ke Zou, Tiarnan D. L. Keenan, Emily Y. Chew, Zhiyong Lu, Yih-Chung Tham, Ninghao Liu, Xiuzhen Zhang, Qingyu Chen

**ÂàÜÁ±ª**: cs.CV

**ÂèëÂ∏ÉÊó•Êúü**: 2025-09-30

---

## üí° ‰∏ÄÂè•ËØùË¶ÅÁÇπ

**ÊèêÂá∫LMOD+ÁúºÁßëÂ§öÊ®°ÊÄÅÊï∞ÊçÆÈõÜ‰∏éÂü∫ÂáÜÔºåÁî®‰∫éËØÑ‰º∞Â§öÊ®°ÊÄÅÂ§ßËØ≠Ë®ÄÊ®°Âûã**

üéØ **ÂåπÈÖçÈ¢ÜÂüü**: **ÊîØÊü±‰πùÔºöÂÖ∑Ë∫´Â§ßÊ®°Âûã (Embodied Foundation Models)**

**ÂÖ≥ÈîÆËØç**: `ÁúºÁßë` `Â§öÊ®°ÊÄÅÂ≠¶‰π†` `Â§ßËØ≠Ë®ÄÊ®°Âûã` `Êï∞ÊçÆÈõÜ` `ÁñæÁóÖËØäÊñ≠` `ÂõæÂÉèÂàÜÊûê` `‰∫∫Â∑•Êô∫ËÉΩ`

## üìã Ê†∏ÂøÉË¶ÅÁÇπ

1. Áé∞ÊúâÁúºÁßëÂ§öÊ®°ÊÄÅÂ§ßËØ≠Ë®ÄÊ®°ÂûãÁº∫‰πèÂÖ®Èù¢ËØÑ‰º∞Âü∫ÂáÜÔºåÈôêÂà∂‰∫ÜÂÖ∂Âú®ÁñæÁóÖËØäÊñ≠ÂíåÂàÜÊúüÁ≠â‰ªªÂä°‰∏äÁöÑÂèëÂ±ï„ÄÇ
2. ÊûÑÂª∫ÂåÖÂê´Â§öÁßçÁúºÁßëÁñæÁóÖÂíåÊàêÂÉèÊ®°ÊÄÅÁöÑÂ§ßËßÑÊ®°Êï∞ÊçÆÈõÜLMOD+ÔºåÂπ∂ËøõË°åÂ§öÁ≤íÂ∫¶Ê†áÊ≥®ÔºåÊîØÊåÅÂ§öÁßç‰ªªÂä°„ÄÇ
3. Á≥ªÁªüËØÑ‰º∞‰∫Ü24‰∏™ÂÖàËøõMLLMÔºåÊè≠Á§∫‰∫ÜÂÖ∂Âú®ÁúºÁßëÁñæÁóÖÁ≠õÊü•‰∏≠ÁöÑÊΩúÂäõÔºå‰ª•ÂèäÂú®Â§çÊùÇ‰ªªÂä°‰∏≠ÁöÑ‰∏çË∂≥„ÄÇ

## üìù ÊëòË¶ÅÔºà‰∏≠ÊñáÔºâ

Êú¨Á†îÁ©∂ÈíàÂØπÂ®ÅËÉÅËßÜÂäõÁöÑÁúºÈÉ®ÁñæÁóÖÔºåÁî±‰∫é‰∏ì‰∏ö‰∫∫ÂëòÁü≠Áº∫ÂíåÂåªÁñóËµÑÊ∫êÈôêÂà∂ÔºåÂèäÊó∂ËØäÊñ≠Èù¢‰∏¥ÊåëÊàò„ÄÇÂ§öÊ®°ÊÄÅÂ§ßËØ≠Ë®ÄÊ®°Âûã(MLLM)Âú®ÂåªÂ≠¶ÂõæÂÉèËß£ÈáäÊñπÈù¢Â±ïÁé∞ÊΩúÂäõÔºå‰ΩÜÁº∫‰πèÈÄÇÁî®‰∫éËØÑ‰º∞ÁîüÊàêÊ®°ÂûãÁöÑÁªºÂêàÂü∫ÂáÜÊï∞ÊçÆÈõÜÈòªÁ¢ç‰∫ÜÂÖ∂Âú®ÁúºÁßëÈ¢ÜÂüüÁöÑÂèëÂ±ï„ÄÇ‰∏∫Ê≠§ÔºåÊàë‰ª¨ÊèêÂá∫‰∫Ü‰∏Ä‰∏™Â§ßËßÑÊ®°Â§öÊ®°ÊÄÅÁúºÁßëÂü∫ÂáÜÊï∞ÊçÆÈõÜLMOD+ÔºåÂåÖÂê´32,633‰∏™ÂÆû‰æãÔºåÊ∂µÁõñ12ÁßçÂ∏∏ËßÅÁúºÁßëÁñæÁóÖÂíå5ÁßçÊàêÂÉèÊñπÂºèÔºåÂπ∂ÂÖ∑ÊúâÂ§öÁ≤íÂ∫¶Ê†áÊ≥®„ÄÇËØ•Êï∞ÊçÆÈõÜÊï¥Âêà‰∫ÜÂõæÂÉè„ÄÅËß£ÂâñÁªìÊûÑ„ÄÅ‰∫∫Âè£ÁªüËÆ°Â≠¶ÂíåËá™Áî±ÊñáÊú¨Ê†áÊ≥®ÔºåÊîØÊåÅËß£ÂâñÁªìÊûÑËØÜÂà´„ÄÅÁñæÁóÖÁ≠õÊü•„ÄÅÁñæÁóÖÂàÜÊúüÂíå‰∫∫Âè£ÁªüËÆ°Â≠¶È¢ÑÊµã‰ª•ËØÑ‰º∞ÂÅèËßÅ„ÄÇÊú¨Â∑•‰ΩúÊâ©Â±ï‰∫ÜÂÖàÂâçÁöÑLMODÂü∫ÂáÜÔºå‰∏ªË¶ÅÊîπËøõÂåÖÊã¨ÔºöÊï∞ÊçÆÈõÜÊâ©Â§ßËøë50%ÔºåÂ§ßÂπÖÂ¢ûÂä†‰∫ÜÂΩ©Ëâ≤ÁúºÂ∫ïÊëÑÂΩ±ÔºõÊâ©Â±ï‰∫Ü‰ªªÂä°ËåÉÂõ¥ÔºåÂåÖÊã¨‰∫åÂÖÉÁñæÁóÖËØäÊñ≠„ÄÅÂ§öÁ±ªËØäÊñ≠„ÄÅÂü∫‰∫éÂõΩÈôÖÂàÜÁ∫ßÊ†áÂáÜÁöÑ‰∏•ÈáçÁ®ãÂ∫¶ÂàÜÁ±ªÂíå‰∫∫Âè£ÁªüËÆ°Â≠¶È¢ÑÊµãÔºõÁ≥ªÁªüËØÑ‰º∞‰∫Ü24‰∏™ÊúÄÂÖàËøõÁöÑMLLM„ÄÇËØÑ‰º∞ÁªìÊûúÊòæÁ§∫‰∫ÜMLLMÁöÑÊΩúÂäõÂíåÂ±ÄÈôêÊÄß„ÄÇÂú®Èõ∂Ê†∑Êú¨ËÆæÁΩÆ‰∏ãÔºåÊÄßËÉΩÊúÄ‰Ω≥ÁöÑÊ®°ÂûãÂú®ÁñæÁóÖÁ≠õÊü•‰∏≠ËææÂà∞‰∫ÜÁ∫¶58%ÁöÑÂáÜÁ°ÆÁéáÔºå‰ΩÜÂú®ÁñæÁóÖÂàÜÊúüÁ≠âÂÖ∑ÊúâÊåëÊàòÊÄßÁöÑ‰ªªÂä°‰∏≠ÔºåÊÄßËÉΩ‰ªçÁÑ∂Ê¨†‰Ω≥„ÄÇÊàë‰ª¨Â∞ÜÂÖ¨ÂºÄÂèëÂ∏ÉÊï∞ÊçÆÈõÜ„ÄÅÁÆ°ÁêÜÊµÅÁ®ãÂíåÊéíË°åÊ¶úÔºå‰ª•‰øÉËøõÁúºÁßë‰∫∫Â∑•Êô∫ËÉΩÂ∫îÁî®ÔºåÂπ∂ÂáèËΩªÂÖ®ÁêÉÂ®ÅËÉÅËßÜÂäõÁöÑÁñæÁóÖË¥üÊãÖ„ÄÇ

## üî¨ ÊñπÊ≥ïËØ¶Ëß£

**ÈóÆÈ¢òÂÆö‰πâ**ÔºöÁé∞ÊúâÁúºÁßëÂ§öÊ®°ÊÄÅÂ§ßËØ≠Ë®ÄÊ®°Âûã(MLLM)ÁöÑÂºÄÂèëÂíåËØÑ‰º∞ÂèóÂà∞Áº∫‰πèÂÖ®Èù¢Âü∫ÂáÜÊï∞ÊçÆÈõÜÁöÑÈôêÂà∂ÔºåÂ∞§ÂÖ∂ÊòØÂú®ÁîüÊàêÊ®°ÂûãÊñπÈù¢„ÄÇÁé∞ÊúâÊñπÊ≥ïÈöæ‰ª•ÊúâÊïàËØÑ‰º∞MLLMÂú®ÁúºÁßëÁñæÁóÖËØäÊñ≠„ÄÅÂàÜÊúüÂíåÂÅèËßÅËØÑ‰º∞Á≠âÊñπÈù¢ÁöÑËÉΩÂäõ„ÄÇ

**Ê†∏ÂøÉÊÄùË∑Ø**ÔºöÊú¨Á†îÁ©∂ÁöÑÊ†∏ÂøÉÊÄùË∑ØÊòØÊûÑÂª∫‰∏Ä‰∏™Â§ßËßÑÊ®°„ÄÅÂ§öÊ®°ÊÄÅ„ÄÅÂ§öÁ≤íÂ∫¶Ê†áÊ≥®ÁöÑÁúºÁßëÊï∞ÊçÆÈõÜLMOD+Ôºå‰ª•Êèê‰æõ‰∏Ä‰∏™ÂÖ®Èù¢ÁöÑÂü∫ÂáÜÔºåÁî®‰∫éËÆ≠ÁªÉÂíåËØÑ‰º∞MLLMÂú®ÁúºÁßëÈ¢ÜÂüüÁöÑÊÄßËÉΩ„ÄÇÈÄöËøáÊï¥ÂêàÂ§öÁßçÊàêÂÉèÊ®°ÊÄÅ„ÄÅËß£ÂâñÁªìÊûÑ„ÄÅ‰∫∫Âè£ÁªüËÆ°Â≠¶‰ø°ÊÅØÂíåËá™Áî±ÊñáÊú¨Ê†áÊ≥®ÔºåLMOD+ËÉΩÂ§üÊîØÊåÅÂ§öÁßç‰ªªÂä°ÔºåÂåÖÊã¨ÁñæÁóÖÁ≠õÊü•„ÄÅÁñæÁóÖÂàÜÊúü„ÄÅËß£ÂâñÁªìÊûÑËØÜÂà´ÂíåÂÅèËßÅËØÑ‰º∞„ÄÇ

**ÊäÄÊúØÊ°ÜÊû∂**ÔºöLMOD+Êï∞ÊçÆÈõÜÁöÑÊûÑÂª∫ÊµÅÁ®ãÂåÖÊã¨Êï∞ÊçÆÊî∂ÈõÜ„ÄÅÊï∞ÊçÆÊ∏ÖÊ¥ó„ÄÅÊï∞ÊçÆÊ†áÊ≥®ÂíåÊï∞ÊçÆÊï¥ÂêàÂõõ‰∏™‰∏ªË¶ÅÈò∂ÊÆµ„ÄÇÊï∞ÊçÆÊî∂ÈõÜÈò∂ÊÆµ‰ªéÂ§ö‰∏™Êù•Ê∫êÊî∂ÈõÜÁúºÁßëÂõæÂÉèÂíåÁõ∏ÂÖ≥‰∏¥Â∫äÊï∞ÊçÆ„ÄÇÊï∞ÊçÆÊ∏ÖÊ¥óÈò∂ÊÆµÂØπÊî∂ÈõÜÂà∞ÁöÑÊï∞ÊçÆËøõË°åÈ¢ÑÂ§ÑÁêÜÔºåÂåÖÊã¨ÂõæÂÉèË¥®ÈáèËØÑ‰º∞„ÄÅÂô™Â£∞ÂéªÈô§ÂíåÊï∞ÊçÆÊ†ºÂºèËΩ¨Êç¢„ÄÇÊï∞ÊçÆÊ†áÊ≥®Èò∂ÊÆµÁî±‰∏ì‰∏öÁöÑÁúºÁßëÂåªÁîüÂØπÂõæÂÉèËøõË°åÂ§öÁ≤íÂ∫¶Ê†áÊ≥®ÔºåÂåÖÊã¨ÁñæÁóÖÁ±ªÂûã„ÄÅÁñæÁóÖ‰∏•ÈáçÁ®ãÂ∫¶„ÄÅËß£ÂâñÁªìÊûÑÂíåËá™Áî±ÊñáÊú¨ÊèèËø∞„ÄÇÊï∞ÊçÆÊï¥ÂêàÈò∂ÊÆµÂ∞ÜÂõæÂÉè„ÄÅÊ†áÊ≥®Âíå‰∫∫Âè£ÁªüËÆ°Â≠¶‰ø°ÊÅØÊï¥ÂêàÂà∞‰∏Ä‰∏™Áªü‰∏ÄÁöÑÊï∞ÊçÆÈõÜ‰∏≠„ÄÇ

**ÂÖ≥ÈîÆÂàõÊñ∞**ÔºöLMOD+ÁöÑÂÖ≥ÈîÆÂàõÊñ∞Âú®‰∫éÂÖ∂Êï∞ÊçÆÈõÜÁöÑËßÑÊ®°„ÄÅÂ§öÊ†∑ÊÄßÂíåÂ§öÁ≤íÂ∫¶Ê†áÊ≥®„ÄÇ‰∏éÁé∞ÊúâÁöÑÁúºÁßëÊï∞ÊçÆÈõÜÁõ∏ÊØîÔºåLMOD+ÂåÖÂê´Êõ¥Â§öÁöÑÊï∞ÊçÆÂÆû‰æã„ÄÅÊõ¥ÂπøÊ≥õÁöÑÁñæÁóÖÁ±ªÂûãÂíåÊàêÂÉèÊ®°ÊÄÅÔºå‰ª•ÂèäÊõ¥ËØ¶ÁªÜÁöÑÊ†áÊ≥®‰ø°ÊÅØ„ÄÇËøôÁßçÂÖ®Èù¢ÁöÑÊï∞ÊçÆÈõÜËÉΩÂ§üÊõ¥Â•ΩÂú∞ÊîØÊåÅMLLMÁöÑËÆ≠ÁªÉÂíåËØÑ‰º∞ÔºåÂπ∂‰øÉËøõÁúºÁßë‰∫∫Â∑•Êô∫ËÉΩÂ∫îÁî®ÁöÑÂèëÂ±ï„ÄÇ

**ÂÖ≥ÈîÆËÆæËÆ°**ÔºöLMOD+Êï∞ÊçÆÈõÜÁöÑÂÖ≥ÈîÆËÆæËÆ°ÂåÖÊã¨Ôºö(1) ÂåÖÂê´‰∫îÁßçÊàêÂÉèÊ®°ÊÄÅÔºöÂΩ©Ëâ≤ÁúºÂ∫ïÊëÑÂΩ±„ÄÅÂÖâÂ≠¶Áõ∏Âπ≤Êñ≠Â±ÇÊâ´Êèè(OCT)„ÄÅOCTË°ÄÁÆ°ÈÄ†ÂΩ±(OCTA)„ÄÅËçßÂÖâÁ¥†Ë°ÄÁÆ°ÈÄ†ÂΩ±(FA)ÂíåÂê≤ÂìöËèÅÁªøË°ÄÁÆ°ÈÄ†ÂΩ±(ICGA)Ôºõ(2) Ê∂µÁõñ12ÁßçÂ∏∏ËßÅÁúºÁßëÁñæÁóÖÔºõ(3) Êèê‰æõÂ§öÁ≤íÂ∫¶Ê†áÊ≥®ÔºåÂåÖÊã¨ÁñæÁóÖÁ±ªÂûã„ÄÅÁñæÁóÖ‰∏•ÈáçÁ®ãÂ∫¶„ÄÅËß£ÂâñÁªìÊûÑÂíåËá™Áî±ÊñáÊú¨ÊèèËø∞Ôºõ(4) ÂåÖÂê´‰∫∫Âè£ÁªüËÆ°Â≠¶‰ø°ÊÅØÔºåÁî®‰∫éËØÑ‰º∞ÂÅèËßÅ„ÄÇ

## üìä ÂÆûÈ™å‰∫ÆÁÇπ

Âú®Èõ∂Ê†∑Êú¨ËÆæÁΩÆ‰∏ãÔºåÊúÄ‰Ω≥MLLMÂú®LMOD+Êï∞ÊçÆÈõÜÁöÑÁñæÁóÖÁ≠õÊü•‰ªªÂä°‰∏≠ËææÂà∞‰∫ÜÁ∫¶58%ÁöÑÂáÜÁ°ÆÁéá„ÄÇËØ•ÁªìÊûúË°®ÊòéMLLMÂú®ÁúºÁßëÁñæÁóÖÁ≠õÊü•ÊñπÈù¢ÂÖ∑ÊúâÊΩúÂäõÔºå‰ΩÜÂêåÊó∂‰πüÊè≠Á§∫‰∫ÜÂÖ∂Âú®ÁñæÁóÖÂàÜÊúüÁ≠âÂ§çÊùÇ‰ªªÂä°‰∏≠‰ªçÂ≠òÂú®Â±ÄÈôêÊÄßÔºåÊú™Êù•‰ªçÊúâÊèêÂçáÁ©∫Èó¥„ÄÇ

## üéØ Â∫îÁî®Âú∫ÊôØ

ËØ•Á†îÁ©∂ÊàêÊûúÂèØÂ∫îÁî®‰∫éÂºÄÂèëËæÖÂä©ÁúºÁßëÁñæÁóÖËØäÊñ≠ÂíåÁÆ°ÁêÜÁöÑAIÁ≥ªÁªüÔºå‰æãÂ¶ÇÔºöËá™Âä®ÁñæÁóÖÁ≠õÊü•„ÄÅÁñæÁóÖÂàÜÊúü„ÄÅÊ≤ªÁñóÊñπÊ°àÊé®ËçêÁ≠â„ÄÇÈÄöËøáÈÉ®ÁΩ≤Âú®Âü∫Â±ÇÂåªÁñóÊú∫ÊûÑÊàñËøúÁ®ãÂåªÁñóÂπ≥Âè∞ÔºåÊúâÊúõÊèêÈ´òËØäÊñ≠ÊïàÁéáÔºåÂáèÂ∞ëËØØËØäÁéáÔºåÂπ∂ÁºìËß£ÁúºÁßëÂåªÁîüÁü≠Áº∫ÁöÑÈóÆÈ¢òÔºåÊúÄÁªàÊîπÂñÑÊÇ£ËÄÖÁöÑËßÜËßâÂÅ•Â∫∑„ÄÇ

## üìÑ ÊëòË¶ÅÔºàÂéüÊñáÔºâ

> Vision-threatening eye diseases pose a major global health burden, with timely diagnosis limited by workforce shortages and restricted access to specialized care. While multimodal large language models (MLLMs) show promise for medical image interpretation, advancing MLLMs for ophthalmology is hindered by the lack of comprehensive benchmark datasets suitable for evaluating generative models. We present a large-scale multimodal ophthalmology benchmark comprising 32,633 instances with multi-granular annotations across 12 common ophthalmic conditions and 5 imaging modalities. The dataset integrates imaging, anatomical structures, demographics, and free-text annotations, supporting anatomical structure recognition, disease screening, disease staging, and demographic prediction for bias evaluation. This work extends our preliminary LMOD benchmark with three major enhancements: (1) nearly 50% dataset expansion with substantial enlargement of color fundus photography; (2) broadened task coverage including binary disease diagnosis, multi-class diagnosis, severity classification with international grading standards, and demographic prediction; and (3) systematic evaluation of 24 state-of-the-art MLLMs. Our evaluations reveal both promise and limitations. Top-performing models achieved ~58% accuracy in disease screening under zero-shot settings, and performance remained suboptimal for challenging tasks like disease staging. We will publicly release the dataset, curation pipeline, and leaderboard to potentially advance ophthalmic AI applications and reduce the global burden of vision-threatening diseases.

